Skip Ribbon Commands
Skip to main content
A- A A+

Find a Doctor

Prof Lim Seng Gee

Photo of Prof Lim Seng Gee
Designations:
  • Senior Consultant, Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital
  • Senior Consultant, Liver Transplantation, National University Centre for Organ Transplantation, National University Hospital
  • Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
  • Director of Hepatology services, Division of Gastroenterology and Hepatology, NUH
  • Expert panel member, Centre for Drug Administration (CPA) and Centre for Drug Evaluation (CDE), Ministry of Health, Singapore
  • Chairman, Singapore Hepatitis Conference (annual), inaugural conference 2014
Qualifications:
MBBS (Hons Monash), FRACP (Aust), FRCP (London), MD (Monash), FAMS (S'pore), Cert Immunology (King's College)
Specialties:
Medicine, Organ Transplantation
Sub-specialties:
Adult Liver Transplantation Programme, Gastroenterology ＆ Hepatology
Special Interests:
Viral Hepatitis, Liver cirrhosis, Liver cancer, Liver disease, Liver Failure, Liver transplantation

Biosketch

Prof Lim currently serves as a Senior Consultant at the Division of Gastroenterology and Hepatology in the National University Hospital, Singapore. He is also a Professor in the Yong Loo Lin School of Medicine, National University of Singapore. 
 
Prof Lim attained his basic medical degree with honours (MBBS Hons) from the University of Monash, Melbourne, Australia. He later pursued a doctorate degree (MD) in Monash and was awarded the FRACP (Australia), FRCP (London), FAMS (Gasteroenterology, Singapore). 
 
He is considered a master clinician having trained over 40 gastroenterologists and hepatologists, and is regularly referred difficult to treat liver cases. His main clinical work focuses on the treatment of viral hepatitis (esp. B and C), liver disease and liver cancer.
 
Prof Lim's research activities include leadership in Hepatology research, which focuses on improving treatment for chronic hepatitis B and C, pathophysiology of hepatitis B disease, HBV virology, immunological mechanisms of HBeAg seroconversion, and loss of immune tolerance to hepatitis B virus. He also has an interest in pathophysiology and treatment of liver cancer, primary hepatocyte culture, hepatocyte function, drug related liver disease and non-alcoholic fatty liver disease.
 
Prof Lim has over 253 publications in peer-reviewed journals with a H-index of 51, and sits on the editorial board of Liver International Hepatology, International, J Viral Hepatitis, Alimentary Pharmacology and Therapeutics, and Lancet Gastroenterology and Hepatology. He has received over S$48 million in research grants. 
 
Prof Lim also sits on the Advisory Board of Novartis Pharmaceuticals, Idenix Pharmaceuticals, Bristol Myers Squibb Pharmaceuticals and is on the Speaker's Bureau for GlaxoSmithKline and Schering Plough Pharmaceuticals. Prof Lim has been an invited speaker at AASLD, EASL and APASL in 2013, 2014 and is a regular speaker at numerous International and Regional meetings on liver disease and viral hepatitis.
 
Prof Lim is also an Evidence Based Medicine (EBM) Champion, having founded the annual Asia Pacific EBM workshop in 2004 together with Prof Tony Dans from the Philippines which still runs yearly, and actively teaches and contributes to the development of EBM in Singapore.
 
Prof Lim is Council member, International Coaliltion for Eradication of Hepatitis B Virus (ICE-HBV), AASLD Asia Pacific Regional Council member, Co-chair ICE-HBV treatment subcommittee, and Co-chair combination therapy subcommittee HBV Forum.

Awards

Blumberg Oration 2016
Clinician Scientist Award Senior Category 2017

Journals & Publications

1) Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):808-16. (tier 1)

2) Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003 Feb 27;348(9):800-7 (tier 1)

3) Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005 Jun 30;352(26):2673-81.

4) Seng Gee Lim, Tay Meng Ng, Nelson Kung, Zahary Krastev, Miroslava Volfova, Petr Husa, Samuel S. Lee, Sing Chan, Mitchell Shiffman, Mary Kay Washington, Amy Rigney, Jane Anderson, Elsa Mondou, Andrea Snow, Jeff Sorbel, Richard Guan, and Franck Rousseau for the Emtricitabine FTCB-301 Study Group. A Double-Blind, Placebo-Controlled Study of Emtricitabine in Patients with Chronic Hepatitis B. Arch Intern Med. 2006 Jan 9;166(1):49-56.

5)  Lim SG, Wai CT, Lee YM, Dan YY, Sutedja DS, Wee A, Suresh S, Wu YJ, Machin D, Lim CC, Fock KM, Koay E, Bowden S, Locarnini S, Ishaque SM. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther. 2006;11(2):245-53.

6) Lim SG, Krastev Z, Ng TM, Mechkov G, Kotzev IA, Chan S, Mondou E, Snow A, Sorbel J, Rousseau F. Randomized, Double-Blind Study of Emtricitabine (FTC) plus Clevudine versus FTC Alone in Treatment of Chronic Hepatitis B Antimicrob Agents Chemother. 2006 May;50(5):1642-8.

7) Seng Gee Lim, Yan Cheng, Stephane Guindon, Bee Leng Seet, Lay Yong Lee, Peizhen Hu, Shanthi Wasser, Frank Josef Peter, Theresa Tan, Matthew Goode, Allen Rodrigo. Viral Quasispecies Evolution During Hepatitis B "e" Antigen Seroconversion. Gastroenterology 2007; 133(3):951-8.

8) Lim SG, Marcellin P, Tassopoulos N, Hadziyannis S, Chang T, Tong M, Sievert W, Hu P, Arterburn S, Brosgart C; On Behalf Of The International Investigator Groups For Studies 437 And 438. Effects of adefovir dipivoxil therapy in asian and caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther. 2007, 26(10):1419-28.

9) Lim SG, Leung N, Hann HW, Lau GK, Trepo C, Mommeja-Marin H, Moxham C, Sorbel J, Snow A, Blum MR, Rousseau F, Marcellin P. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2008 Jun;27(12):1282-92.

10) Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010 Mar 18;4(2):439-74.

11) Wiersma ST, McMahon B, Pawlotsky JM, Thio CL, Thursz M, Lim SG, Ocama P, Esmat G, Maimuna M, Bell D, Vitoria M, Eramova I, Lavanchy D, Dusheiko G. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int. 2011; 31(6):755-61.

12) Masao Omata, Tatsuo Kanda, Ming-Lung Yu, Osamu Yokosuka, Seng-Gee Lim, Wasim Jafri, Ryosuke Tateishi, Saeed S. Hamid, Wan-Long Chuang,Anuchit Chutaputti, Lai Wei, Jose Sollano, Shiv Kumar Sarin, Jia-Horng Kao, and Geoffrey W. McCaughan. APASL Consensus Statements and Management Algorithms for Hepatitis C Virus Infection, Hepatology Int 2012; 6:409–435.

13) Yun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, Henry LY Chan, Rong-Nan Chien, Chun-Jen Liu, Edward Gane, Stephen Locarnini, Seng-Gee Lim, Kwang-Hyub Han, Graham Cooksley, S.M. Wasim Jafri, Rosmatwati Mohammed, Deepak Amarapurkar, Jin-Lin Hou, Wan-Long Chuang, Laurentius Lesmana, Jose Sollarno, Dong-Jin Suh, Masao Omata, Asia-Pacific Consensus Statement on the Management of Chronic Hepatitis B: a 2012 update. Hepatol Int 2012;6:409–435.

14) Cheng Y, Guindon S, Rodrigo A, Lim SG. Increased Viral Quasispecies Evolution in Hbeag Seroconverter Patients Treated with Oral Nucleoside Therapy. J Hepatol. 2013;58(2):217-24.

15) Yan Cheng, Stephane Guindon, Allen Rodrigo, Lin Ying Wee, Masafumi Inoue, Alex Thompson, Stephen Locarnini, Seng Gee Lim. Cumulative Viral Evolutionary Changes In Chronic Hepatitis B Virus Infection Precedes HBeAg Seroconversion. Gut. 2013 Sep;62(9):1347-55. doi: 10.1136/gutjnl-2012-302408. Epub 2012 Dec 15.

16) Lim SG, Amarapurkar DN, Chan HL, Crawford DH, Gane EJ, Han KH, Ahn SH, Jafri W, Jia J, Kao JH, Lesmana LA, Lesmana CR, Mohamed R, Phiet PH, Piratvisuth T, Sarin SK, Sollarno JD, Eguchi Y, Mahtab MA, Lee KH. Reimbursement policies in the Asia-Pacific for chronic hepatitis B. Hepatol Int. 2015 Jan;9(1):43-51.

17) Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, Petersen J, Foster GR, Lou L, Martins EB, Dinh P, Lin L, Corsa A, Charuworn P, Subramanian GM, Reiser H, Reesink HW, Fung S, Strasser SI, Trinh H, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HL; study 149 investigators. Combination of Tenofovir Disoproxil Fumarate and Peginterferon alfa-2a Increases Loss of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B. Gastroenterology. 2015 Oct 7. pii: S0016-5085(15)01429-8. doi: 10.1053/j.gastro.2015.09.043. [Epub ahead of print].

18) Visvanathan K, Dusheiko G, Giles M, Wong ML, Phung N, Walker S, Le S, Lim SG, Gane E, Ngu M, Hardikar W, Cowie B, Bowden S, Strasser S, Levy M, Sasaduesz J. Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.  Gut. 2015 Oct 15. pii: gutjnl-2015-310317. doi: 10.1136/gutjnl-2015-310317. [Epub ahead of print] Review.

19) Feld J, Janssen HL, Abbas Z, Elewaut A, Ferenci P, Isakov V, Khan AG, Lim SG, Locarnini SA, Ono SK, Sollano J, Spearman CW, Yeh CT, Yuen MF, LeMair A; Review Team. World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. J Clin Gastroenterol. 2016 Oct;50(9):691-703.

20) Seng Gee Lim, Alessio Aghemo, Pei-Jer Chen, Yock Young Dan, Edward Gane, Rino Gani, Robert G Gish, Richard Guan, Ji Dong Jia, Kieron Lim, Teerha Piratvisuth, Samir Shah, Mitchell L Shiffman, Frank Tacke, Soek Siam Tan, Tawesak Tanwandee, Khin Maung Win, Cihan Yurdaydin. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol 2017; 2: 52–62.

21) Chong CH, Lim SG. When can we stop nucleoside analogues in patients with chronic hepatitis B? Liver Int. 2017 Jan;37 Suppl 1:52-58. doi: 10.1111/liv.13314. Review.

22) Lim SG. HCV management in resource-constrained countries. Hepatol Int. 2017 May;11(3):245-254. doi: 10.1007/s12072-017-9787-0. Epub 2017 Feb 21. Review.

23) Anderson RT, Lim SG, Mishra P, Josephson F, Donaldson E, Given B, Miller V. Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic HBV. Gastroenterology. 2018 Dec 4. pii: S0016-5085(18)35378-2. doi: 10.1053/j.gastro.2018.11.062. [Epub ahead of print].

24) Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R; Members of the ICE-HBV Working Groups; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F.A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. doi: 10.1016/S2468-1253(19)30119-0. Epub 2019 Apr 10. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e7.

25) Lim SG, Agcaoili J, De Souza NNA, Chan E. Therapeutic vaccination for chronic hepatitis B: A systematic review and meta-analysis. J Viral Hepat. 2019 Jul;26(7):803-817.

26) Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, Jia J, Tian Q, Aggarwal R, Muljono DH, Omata M, Ooka Y, Han KH, Lee HW, Jafri W, Butt AS, Chong CH, Lim SG, Pwu RF, Chen DS. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):167-228.

27) Fonseca MA, Ling JZJ, Al-Siyabi O, Co-Tanko V, Chan E, Lim SG. The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta-analysis. J Viral Hepat. 2020 Jul;27(7):650-662.

28) Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, Susilo A, Tanaka Y, Chan WK, Gane E, Ong-Go AK, Lim SG, Ahn SH, Yu ML, Piratvisuth T, Chan HL; Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-787. doi: 10.1016/S2468-1253(20)30190-4. Epub 2020 Jun 23.

Professional Memberships

Fellow of the Royal Australasian College of Physicians
Fellow of the Royal College of Physicians of London
Member, Gastroenterological Society of Singapore
Member, Gastroenterological Society of Australia
Fellow, Academy of Medicine of Singapore
Fellow, American Association for Liver Disease
Member, European Association for Study of Liver

Contact

Appt Tel:
+65 6772 2002
Fax:
+65 6772 4361
URL:
https://www.nuh.com.sg/medicine
https://www.nuh.com.sg/nucot

National University Health System
  • National University Hospital
  • Ng Teng Fong General Hospital
  • Alexandra Hospital
  • Jurong Community Hospital
  • National University Polyclinics
  • Jurong Medical Centre
  • National University Cancer Institute, Singapore
  • National University Heart Centre, Singapore
  • National University Centre for Oral Health, Singapore (NUCOHS)
  • NUS - Yong Loo Lin, School of Medicine
  • NUS - Faculty of Dentistry
  • NUS - Saw Swee Hock, School of Public Health